直接口服抗凝剂剂量不足和过量的决定因素以及医生对临床药师建议的执行情况。
Determinants for under- and overdosing of direct oral anticoagulants and physicians' implementation of clinical pharmacists' recommendations.
机构信息
Research Group Clinical Pharmacology and Clinical Pharmacy, Vrije Universiteit Brussel, Jette, Belgium.
出版信息
Br J Clin Pharmacol. 2022 Feb;88(2):753-763. doi: 10.1111/bcp.15017. Epub 2021 Aug 21.
AIMS
To analyse the appropriateness of direct oral anticoagulant (DOAC) dosing and determinants for under-and overdosing as well as acceptance and implementation rates of pharmacists' interventions.
METHODS
Cross-sectional study in a tertiary hospital in hospitalized patients with atrial fibrillation on DOACs in 2019 (n = 1688). Primary outcome was the proportion of patients with inappropriate DOAC prescribing with identification of determinants for under-and overdosing. Secondary outcomes included acceptance and implementation rates of pharmacists' recommendations and determination of reasons for nonacceptance/nonimplementation.
RESULTS
Inappropriate prescribing was observed in 16.9% of patients (n = 286) with underdosing (9.7%) being more prevalent than overdosing (6.9%). For all DOACs considered together, body weight<60 kg (odds ratio [OR] 0.46 [0.27-0.77]), edoxaban use (OR 0.42 [0.24-0.74]), undergoing surgery (OR 0.57 [0.37-0.87]) and being DOAC naïve (OR 0.45 [0.29-0.71]) were associated with significantly lower odds of underdosing. Bleeding history (OR 1.86 [1.24-2.80]) and narcotic use (OR 1.67 [1.13-2.46]) were associated with significantly higher odds for underdosing. Determinants with a significantly higher odds of overdosing were renal impairment (OR 11.29 [6.23-20.45]) and body weight<60 kg (OR 2.34 [1.42-3.85]), whereas dabigatran use (OR 0.24 [0.08-0.71]) and apixaban (OR 0.18 [0.10-0.32]) were associated with a significantly lower odds of overdosing compared to rivaroxaban. Physicians accepted the pharmacists' advice in 179 cases (79.2%) consisting of 92 (51.4%) recommendations for underdosing, 82 (45.8%) for overdosing and 5 (2.8%) for contraindications.
CONCLUSION
Inappropriate DOAC prescribing remains common, although there is a slight improvement compared to our study of 2016. Clinical services led by pharmacists help physicians to reduce the number of inadequate prescriptions for high-risk medications such as DOACs.
目的
分析直接口服抗凝剂(DOAC)剂量的适宜性,以及剂量不足和过量的决定因素,以及药剂师干预的接受和实施率。
方法
2019 年在一家三级医院对接受 DOAC 治疗的心房颤动住院患者进行横断面研究(n=1688)。主要结局是确定剂量不足和过量的决定因素,评估患者 DOAC 处方的不适当比例。次要结局包括药剂师建议的接受和实施率,以及确定不接受/不实施的原因。
结果
16.9%(n=286)的患者存在不适当的处方,剂量不足(9.7%)比剂量过量(6.9%)更为常见。对于所有考虑的 DOAC 药物,体重<60kg(比值比 [OR] 0.46 [0.27-0.77])、使用依度沙班(OR 0.42 [0.24-0.74])、接受手术(OR 0.57 [0.37-0.87])和 DOAC 初治(OR 0.45 [0.29-0.71])与剂量不足的可能性显著降低相关。有出血史(OR 1.86 [1.24-2.80])和使用麻醉药物(OR 1.67 [1.13-2.46])与剂量不足的可能性显著增加相关。与剂量过量可能性显著增加相关的决定因素是肾功能损害(OR 11.29 [6.23-20.45])和体重<60kg(OR 2.34 [1.42-3.85]),而达比加群(OR 0.24 [0.08-0.71])和阿哌沙班(OR 0.18 [0.10-0.32])的使用与 rivaroxaban 相比,剂量过量的可能性显著降低。医生接受了药剂师的建议,其中包括 92 例(51.4%)剂量不足、82 例(45.8%)剂量过量和 5 例(2.8%)禁忌证的建议。
结论
尽管与我们 2016 年的研究相比略有改善,但不适当的 DOAC 处方仍然很常见。由药剂师主导的临床服务有助于医生减少高危药物(如 DOAC)的不适当处方数量。